The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Ronan Swords receives Pap Corps Endowed Professorship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

RONAN SWORDS received the Pap Corps Endowed Professorship in Leukemia at the University of Miami Sylvester Comprehensive Cancer Center. Swords is assistant professor of medicine and director of the Leukemia Program at Sylvester.

The endowment comes from The Pap Corps: Champions for Cancer Research, a volunteer organization that raises money solely for cancer research at Sylvester. The organization has donated more than $51 million to the center, including this year’s $4.5 million as part of an overall pledge of $25 million to University of Miami’s Momentum2 campaign.

Swords is a fellow of the Royal College of Physicians in Ireland and the Royal College of Pathologists in London. He came to the U.S. in 2009 for an advanced fellowship in drug development at the University of Texas Health Science Center. Swords joined Sylvester in 2012.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
By W. Kimryn Rathmell
Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account